General MedicationsINJECTIONStandard
VEOPOZ
POZELIMAB-BBFG
Standard Dose
400MG/2ML(200MG/ML)
Max Dose
Refer to approved labeling
Primary Use
Review priority: PRIORITY Marketing status: Prescription
Summary
Approval overview VEOPOZ is listed in Drugs@FDA under application 761339 (BLA).
Review priority: PRIORITY Marketing status: Prescription Active ingredient POZELIMAB-BBFG Form and strength INJECTABLE;INJECTION - 400MG/2ML(200MG/ML) Sponsor REGENERON PHARMACEUTICALS Submission history Latest submission status date: 2023-08-18 00:00:00.
Structured Monograph
Clinical summary
Approval overview VEOPOZ is listed in Drugs@FDA under application 761339 (BLA). Review priority: PRIORITY Marketing status: Prescription Active ingredient POZELIMAB-BBFG Form and strength INJECTABLE;INJECTION - 400MG/2ML(200MG/ML) Sponsor REGENERON PHARMACEUTICALS Submission history Latest submission status date: 2023-08-18 00:00:00. Submission type: ORIG.
Monitoring
- • Marketing status: Prescription
- • Review priority: PRIORITY
Interaction Notes
- No interaction notes stored yet.